1. Corder G, Castro DC, Bruchas MR, Scherrer G. Endogenous and exogenous opioids in pain. Annu Rev Neurosci. 2018; 41:453-73. [DOI:10.1146/annurev-neuro-080317-061522] [PMID] [PMCID] [
DOI:10.1146/annurev-neuro-080317-061522]
2. Listos J, Łupina M, Talarek S, Mazur A, Orzelska-Górka J, Kotlińska J. The mechanisms involved in morphine addiction: An overview. Int J Mol Sci. 2019; 20(17):4302. [DOI:10.3390/ijms20174302] [PMID] [
DOI:10.3390/ijms20174302]
3. Wise RA, Robble MA. Dopamine and addiction. Annu Rev Psychol. 2020; 71:79-106. [DOI:10.1146/annurev-psych-010418-103337] [PMID] [
DOI:10.1146/annurev-psych-010418-103337]
4. Rivera A, Suárez-Boomgaard D, Miguelez C, Valderrama-Carvajal A, Baufreton J, Shumilov K, et al. Dopamine D4 receptor is a regulator of morphine-induced plasticity in the rat dorsal striatum. Cells. 2021; 11(1):31. [DOI:10.3390/cells11010031] [PMID] [
DOI:10.3390/cells11010031]
5. Trifilieff P, Martinez D. Imaging addiction: D2 receptors and dopamine signaling in the striatum as biomarkers for impulsivity. Neuropharmacology. 2014; 76 Pt B(0):498-509. [DOI:10.1016/j.neuropharm.2013.06.031] [PMID] [
DOI:10.1016/j.neuropharm.2013.06.031]
6. Funada M, Shippenberg TS. Differential involvement of D1 and D2 dopamine receptors in the expression of morphine withdrawal signs in rats. Behav Pharmacol. 1996; 7(5):448-53.[PMID]
7. Dai WL, Xiong F, Yan B, Cao ZY, Liu WT, Liu JH, et al. Blockade of neuronal dopamine D2 receptor attenuates morphine tolerance in mice spinal cord. Sci Rep. 2016; 6:38746. [DOI:10.1038/srep38746] [PMID] [PMCID] [
DOI:10.1038/srep38746]
8. Liu J, Nickolenko J, Sharp FR. Morphine induces c-fos and junB in striatum and nucleus accumbens via D1 and N-methyl-D-aspartate receptors. Proc Natl Acad Sci U S A. 1994; 91(18):8537-41. [DOI:10.1073/pnas.91.18.8537] [PMID] [
DOI:10.1073/pnas.91.18.8537]
9. Rivera A, Gago B, Suárez-Boomgaard D, Yoshitake T, Roales-Buján R, Valderrama-Carvajal A, et al. Dopamine D4 receptor stimulation prevents nigrostriatal dopamine pathway activation by morphine: Relevance for drug addiction. Addict Biol. 2017; 22(5):1232-45. [DOI:10.1111/adb.12407] [PMID] [
DOI:10.1111/adb.12407]
10. Georges F, Stinus L, Bloch B, Le Moine C. Chronic morphine exposure and spontaneous withdrawal are associated with modifications of dopamine receptor and neuropeptide gene expression in the rat striatum. Eur J Neurosci. 1999; 11(2):481-90. [DOI:10.1046/j.1460-9568.1999.00462.x] [PMID] [
DOI:10.1046/j.1460-9568.1999.00462.x]
11. Suárez-Boomgaard D, Gago B, Valderrama-Carvajal A, Roales-Buján R, Van Craenenbroeck K, Duchou J, et al. Dopamine D₄ receptor counteracts morphine-induced changes in µ opioid receptor signaling in the striosomes of the rat caudate putamen. Int J Mol Sci. 2014; 15(1):1481-98. [DOI:10.3390/ijms15011481] [PMID] [
DOI:10.3390/ijms15011481]
12. Elias AM, Pepin MJ, Brown JN. Adjunctive memantine for opioid use disorder treatment: A systematic review. J Subst Abuse Treat. 2019; 107:38-43. [DOI:10.1016/j.jsat.2019.10.003] [PMID] [
DOI:10.1016/j.jsat.2019.10.003]
13. Seeman P, Caruso C, Lasaga M. Memantine agonist action at dopamine D2High receptors. Synapse. 2008; 62(2):149-53. [DOI:10.1002/syn.20472] [PMID] [
DOI:10.1002/syn.20472]
14. Marvanová M, Lakso M, Pirhonen J, Nawa H, Wong G, Castrén E. The neuroprotective agent memantine induces brain-derived neurotrophic factor and trkB receptor expression in rat brain. Mol Cell Neurosci. 2001; 18(3):247-58. [DOI:10.1006/mcne.2001.1027] [PMID] [
DOI:10.1006/mcne.2001.1027]
15. Rostami F, Oryan S, Ahmadiani A, Dargahi L. Morphine preconditioning protects against LPS-induced neuroinflammation and memory deficit. J Mol Neurosci. 2012; 48(1):22-34. [DOI:10.1007/s12031-012-9726-4] [PMID] [
DOI:10.1007/s12031-012-9726-4]
16. Alderks CE. Trends in the use of methadone, buprenorphine, and extended-release naltrexone at substance abuse treatment facilities: 2003-2015 (update). Rockville: Ubstance Abuse and Mental Health Services Administration; 2017. [PMID]
17. Ayanga D, Shorter D, Kosten TR. Update on pharmacotherapy for treatment of opioid use disorder. Expert Opin Pharmacother. 2016; 17(17):2307-18. [DOI:10.1080/14656566.2016.1244529] [PMID] [
DOI:10.1080/14656566.2016.1244529]
18. Nestler EJ. Molecular mechanisms of drug addiction. Neuropharmacology. 2004;47(Suppl 1):24-32. [DOI:10.1016/j.neuropharm.2004.06.031] [PMID] [
DOI:10.1016/j.neuropharm.2004.06.031]
19. Abul-Husn NS, Annangudi SP, Ma'ayan A, Ramos-Ortolaza DL, Stockton SD Jr, Gomes I, et al. Chronic morphine alters the presynaptic protein profile: Identification of novel molecular targets using proteomics and network analysis. Plos One. 2011; 6(10):e25535. [DOI:10.1371/journal.pone.0025535] [PMID] [PMCID] [
DOI:10.1371/journal.pone.0025535]
20. Volkow ND, Fowler JS, Wang GJ, Swanson JM, Telang F. Dopamine in drug abuse and addiction: Results of imaging studies and treatment implications. Arch Neurol. 2007; 64(11):1575-9 [DOI:10.1001/archneur.64.11.1575] [PMID] [
DOI:10.1001/archneur.64.11.1575]
21. Yu G, Yan H, Gong ZH. Differential effects of acute and repeated morphine treatment on κ-opioid receptor mRNA levels in mesocorticolimbic system. Pharmacol Rep. 2012; 64(2):445-8. [DOI:10.1016/S1734-1140(12)70786-7] [PMID] [
DOI:10.1016/S1734-1140(12)70786-7]
22. Yu G, Yan H, Gong ZH. Effects of acute and repeated morphine treatment on κ-opioid receptor protein levels in mesocorticolimbic system. J Recept Signal Transduct Res. 2014; 34(1):44-7. [DOI:10.3109/10799893.2013.856919] [PMID] [
DOI:10.3109/10799893.2013.856919]
23. Nair VD, Savelli JE, Mishra RK. Modulation of dopamine D2 receptor expression by an NMDA receptor antagonist in rat brain. J Mol Neurosci. 1998; 11(2):121-6. [DOI:10.1385/JMN:11:2:121] [PMID] [
DOI:10.1385/JMN:11:2:121]
24. Verma A, Kulkarni SK. Role of D1/D2 dopamine and N-methyl-D-aspartate (NMDA) receptors in morphine tolerance and dependence in mice. Eur Neuropsychopharmacol. 1995; 5(2):81-7. [DOI:10.1016/0924-977X(94)00140-7] [PMID] [
DOI:10.1016/0924-977X(94)00140-7]
25. Semenova S, Danysz W, Bespalov A. Low-affinity NMDA receptor channel blockers inhibit acquisition of intravenous morphine self-administration in naive mice. Eur J Pharmacol. 1999; 378(1):1-8. [DOI:10.1016/S0014-2999(99)00431-8] [PMID] [
DOI:10.1016/S0014-2999(99)00431-8]
26. Chen Y, Evola M, Young AM. Memantine and dizocilpine interactions with antinociceptive or discriminative stimulus effects of morphine in rats after acute or chronic treatment with morphine. Psychopharmacology. 2013; 225(1):187-99.[DOI:10.1007/s00213-012-2807-9] [PMID] [PMCID] [
DOI:10.1007/s00213-012-2807-9]
27. Chen SL, Tao PL, Chu CH, Chen SH, Wu HE, Tseng LF, et al. Low-dose memantine attenuated morphine addictive behavior through its anti-inflammation and neurotrophic effects in rats. J Neuroimmune Pharmacol. 2012; 7(2):444-53. [DOI:10.1007/s11481-011-9337-9] [PMID] [PMCID] [
DOI:10.1007/s11481-011-9337-9]
28. Sukhotina IA, Bespalov AY. Effects of the NMDA receptor channel blockers memantine and MRZ 2/579 on morphine withdrawal-facilitated aggression in mice. Psychopharmacology. 2000; 149(4):345-50. [DOI:10.1007/s002130000386] [PMID] [
DOI:10.1007/s002130000386]
29. Gonzalez G, DiGirolamo G, Romero-Gonzalez M, Smelson D, Ziedonis D, Kolodziej M. Memantine improves buprenorphine/naloxone treatment for opioid dependent young adults. Drug Alcohol Depend. 2015; 156:243-53. [DOI:10.1016/j.drugalcdep.2015.09.020] [PMID] [
DOI:10.1016/j.drugalcdep.2015.09.020]
30. Popik P, Skolnick P. The NMDA antagonist memantine blocks the expression and maintenance of morphine dependence. Pharmacol Biochem Behav. 1996; 53(4):791-7. [DOI:10.1016/0091-3057(95)02163-9] [PMID] [
DOI:10.1016/0091-3057(95)02163-9]
31. Ribeiro Do Couto B, Aguilar MA, Manzanedo C, Rodríguez-Arias M, Miñarro J. Effects of NMDA receptor antagonists (MK-801 and memantine) on the acquisition of morphine-induced conditioned place preference in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2004; 28(6):1035-43. [DOI:10.1016/j.pnpbp.2004.05.038] [PMID] [
DOI:10.1016/j.pnpbp.2004.05.038]
32. Zhou X, Wang L, Xiao W, Su Z, Zheng C, Zhang Z, et al. Memantine Improves cognitive function and alters hippocampal and cortical proteome in triple transgenic mouse model of Alzheimer's Disease. Exp Neurobiol. 2019; 28(3):390-403. [DOI:10.5607/en.2019.28.3.390] [PMID] [
DOI:10.5607/en.2019.28.3.390]
33. Lannes B, Micheletti G, Warter JM, Zwiller J. [Chronic administration of N-methyl-D-aspartate (NMDA) receptor antagonists induced in rats, a facilitation of striatal dopaminergic type D2 transmission: Behavioral and biochemical study (French)]. C R Acad Sci III. 1992; 315(10):387-94. [PMID]
34. Maler JM, Esselmann H, Wiltfang J, Kunz N, Lewczuk P, Reulbach U, et al. Memantine inhibits ethanol-induced NMDA receptor up-regulation in rat hippocampal neurons. Brain Res. 2005; 1052(2):156-62.[DOI:10.1016/j.brainres.2005.06.017] [PMID] [
DOI:10.1016/j.brainres.2005.06.017]